Clinical Trials Browser

Phase 2/3 × Dexamethasone × Plasma cell × Clear all

NCT07095452 2026-03-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

Multiple Myeloma

NCT07428369 2026-02-23

LINKER-MM8

Phase 2/3 Not yet recruiting

Multiple Myeloma

NCT04513639 2025-03-20

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Phase 2/3 Recruiting

Multiple Myeloma

NCT06879379 2025-03-17

KPD Consolidation After ASCT in NDMM Patients

Phase 2/3 Recruiting

Multiple Myeloma

NCT03759093 2023-09-06

CURATE.AI Optimized Modulation for Multiple Myeloma

Phase 2/3 Unknown

Multiple Myeloma

NCT00038090 2018-10-31

Thalidomide-Dexamethasone for Multiple Myeloma

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02419118 2017-11-07

DARA

Phase 2/3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00861250 2016-06-17

Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

Phase 2/3 Completed

Multiple Myeloma